Fredrik Schjesvold, MD, PhD, Discusses Key Findings From the OCEAN Trial in Relapsed/Refractory Multiple Myeloma

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to discuss key data that read out from the OCEAN trial for relapsed/refractory multiple myeloma.

At the 2021 International Myeloma Workshop, CancerNetwork® spoke with Fredrik Schjesvold, MD, PhD, founder and head of the Oslo Myeloma Center, about key highlights from the phase 3 OCEAN trial (NCT03151811).


The key data for this study is a bit complex. The primary end point [of progression-free survival] (PFS) is definitely better than pomalidomide [Pomalyst]/[dexamethasone]. In the total population, even though it [was not] statistically significant, [there was] an increase in death rates in the melflufen [Pepaxto] arm, which has led to partial clinical hold for ongoing studies with this drug. What we have [demonstrated in the OCEAN trial] is that [the] overall survival [OS] detriment is mainly for the patients who are transplanted, especially recently. For the patients who were not transplanted, the benefit of melflufen was even higher for PFS and also present for overall survival [OS]. For the patients who were transplanted, they benefitted more from pomalidomide, both in PFS and especially in OS.

Most randomized studies in myeloma are add-ons to this, where you have a standard and you add a new treatment. Then you get, more or less, not so interesting subgroups because they all benefit. [However], this is a head-to-head study with 2 different types of drugs, and then you get more interesting results from the subgroups, showing that some patients do benefit from 1 of the arms and the other subgroup benefits from the other treatment. Since transplants were present in about 50% of the total population, these are sort of large subgroups. It’s half of the population each and it’s quite clear that melflufen is beneficial for the patients who are not transplanted and opposite for the patients who are transplanted with the benefit from pomalidomide.


Schjesvold F, Dimopoulos MA, Delimpasi S, et al. OCEAN (OP-103): a Phase 3, randomized, global, head-to-head comparison study of melflufen and dexamethasone (Dex) versus pomalidomide (Pom) and dex in relapsed refractory multiple myeloma (RRMM). Presented at: International Myeloma Workshop; September 8-11, 2021; Vienna, Austria. Accessed September 11, 2021.

Related Videos
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
Experts on multiple myeloma
Experts on multiple myeloma
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Experts on multiple myeloma
Experts on multiple myeloma
Related Content